Moderna Reports $1.3B Q1 Net Loss Driven by Litigation Charge, Reiterates 2026 Growth Outlook
summarizeSummary
Moderna reported first quarter 2026 revenue of $0.4 billion, an increase from the prior year, but a GAAP net loss of $(1.3) billion, or $(3.40) per share. The net loss was significantly impacted by a non-recurring $0.9 billion litigation settlement charge. Excluding this charge, the company reiterated its plan for up to 10% revenue growth and GAAP operating expense reductions in 2026. The report also highlighted recent European regulatory approvals for mNEXSPIKE and mCOMBRIAX (its flu plus COVID combination vaccine), the latter of which was previously announced on April 21st. Additionally, Moderna initiated a new Phase 3 clinical study for intismeran autogene in non-small cell lung cancer. While the headline net loss is larger year-over-year, the underlying operational performance, positive guidance reiteration, and pipeline advancements present a mixed picture for investors. Traders will be watching how the market weighs the one-time charge against the company's operational improvements and future growth catalysts, including upcoming pivotal readouts for norovirus and other programs.
At the time of this announcement, MRNA was trading at $48.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.2B. The 52-week trading range was $22.28 to $59.55. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Access Newswire.